Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Company to commence first in man studies with its next generation VEGF Antagonist in the first half of 2010
Subscribe to our email newsletter
Pieris has reported continued progress in the development of its lead therapeutic program for the clinic. Under its manufacturing agreement with Wacker Biotech, Pieris has completed the first cGMP run of its Anticalin candidate PRS-050, a potent VEGF antagonist with broad therapeutic applicability.
In connection with the production process parameters for PRS-050 earlier in 2009, Pieris has now met all regulatory CMC requirements to file an IND application by the end of January 2010.
Reportedly, with toxicology studies, PRS-050 is scheduled to commence first in man studies in the first half of 2010.
The company said that the progress in the PRS-050 program demonstrates that Anticalin discovery programs can be successfully advanced from lead candidate to GMP production in around twelve months.
Claus Schalper, interim-CEO at Pieris, said: “Sustained progress in development of PRS-050 underscores our commitment to advancing our lead Anticalin program into the clinic as quickly and efficiently as possible. This is in line with Pieris’ strategy to bring Anticalins into the clinics while partnering selected project at an earlier development stage.”